[pubmed] The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients
Posté : 25 sept. 2020 12:00
J Neuroimmunol. 2020 Sep 21;349:577402. doi: 10.1016/j.jneuroim.2020.577402. Online ahead of print.
ABSTRACT
B cells play a major role in the pathophysiology of myasthenia gravis (MG) with their ability to produce disease specific, pathogenic antibodies. However, their status during disease development and follow-up stages of the disease in the peripheral blood may need further studies to determine useful markers. In this study, we aimed to detect B cell associated factors concerning immunosuppressive treatment in generalized non-thymomatous MG patients. Although CD19+ B cell distribution did not vary among disease subgroups, expressions of both CD38 and BAFFR were altered on B cells in MG patients under immunosuppressive therapy. Serum levels of BAFF were elevated in untreated MG patients as compared to treated MG patients and healthy controls. B cell activation factors may show profound alterations due to immunosuppression.
PMID:32977248 | DOI:10.1016/j.jneuroim.2020.577402
Source: https://pubmed.ncbi.nlm.nih.gov/3297724 ... 1&v=2.11.5